You are here: Industry Insights > Rituxan

News List

Polivy® with R-CHP significantly improves lymphoma outcomes europeanpharmaceuticalreview
August 10, 2021
Polivy with MabThera/Rituxan and R-CHP is the first regimen in 20 years to improve significantly outcomes in a previously untreated form of lymphoma, Phase III study shows.
I-Mab Accelerates Clinical Development of Anti-CD47 Monoclonal Antibody Lemzoparlimab in the US and China prnasia
December 07, 2020
I-Mab announced the advancement of clinical development of the highly differentiated anti-CD47 monoclonal antibody lemzoparlimab (also known as TJC4) in the US and China, achieving milestones as planned.
Ten drugs in pre-registration phase have potential to reach blockbuster status by 2025: GlobalData expresspharma
March 13, 2020
Amgen and Allergan’s biosimilar candidate to Roche’s Rituxan (rituximab) shows the greatest potential of these drugs.
Amgen and Allergan announce positive top-line results from comparative clinical study of ABP 798, biosimilar candidate to Rituxan® (rituximab) worldpharmanews
August 23, 2019
Amgen and Allergan plc. announced positive top-line results from a comparative clinical study evaluating the efficacy and safety of ABP 798...
FDA Approves Ruxience (rituximab-pvvr), a Biosimilar to Rituxan drugs
July 24, 2019
Pfizer Inc. announced the United States (U.S.) Food and Drug Administration (FDA) has approved Ruxience (rituximab-pvvr)...
Rituxan hits endpoints in late-stage skin disease trial pharmatimes
June 16, 2019
Roche has announced that its monoclonal antibody, Rituxan (rituximab), met all primary and secondary endpoints in the Phase III PEMPHIX study.
The 1st Chinese-produced Biosimilar Approved for Marketing PharmaSources/Yuntian
March 20, 2019
We would find out the reason if we looked into the situation of the original drug of rituximab
Amgen, Allergan Announce Positive Top-Line Results from ABP 798 Study americanpharmaceuticalreview
January 25, 2019
Amgen and Allergan announced positive top-line results from a Phase 1/ Phase 3 study evaluating the pharmacokinetics, efficacy and safety of biosimilar candidate ABP 798....
Sandoz axes filing of US Rituxan biosimilar pharmaphorum
December 14, 2018
Sandoz has abandoned plans to get a cheaper biosimilar of Swiss rival Roche’s cancer drug Rituxan (rituximab) approved in the US.
Pfizer's biosimilar proves non-inferior to rituximab in lymphoma at ASH 2018 pharmafile
December 07, 2018
Joining the chorus of data presentations at the American Society of Hematology (ASH) Annual Meeting 2018, Pfizer has announced new data for its biosimilar version of Genentech’s

Previous page 1 2 3 Next page